

## INFORMATION DISCLOSURE STATEMENT

Applicant : Andersson et al.  
App. No : 10/802,970  
Filed : March 16, 2004  
For : AZACYCLIC COMPOUNDS  
Examiner : Jason H. Johnsen  
Art Unit : 1624

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 132 references to be considered by the Examiner. Also enclosed are 119 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

With respect to Reference 16, an English translation was not available. However, U.S. Patent No. 5,025,013 (Reference 2) is believed to contain the relevant portions in English.

With respect to Reference 56, an English translation was not available. However, the relevant portion is believed to be the chemical structures shown throughout the article.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required. If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

By: Daniel Hart

Daniel Hart  
Registration No. 40,637  
Attorney of Record  
Customer No. 20,995  
(619) 235-8550

Dated: March 20, 2007

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Multiple sheets used when necessary)</i>		Application No.	10/802,970
		Filing Date	March 16, 2004
		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (If Known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	4,138,492	02-06-1979	Noverola, et al.	
	2	5,025,013	06-18-1991	Barreau, et al.	
	3	5,214,055	05-25-1993	Peglion, et al.	
	4	5,461,086	10-24-1995	Gerlicke, et al.	
	5	5,821,010	04-15-1997	Sueda, et al.	
	6	5,795,894	08-18-1998	Shue, et al.	
	7	5,869,488	02-09-1999	Shue, et al.	
	8	5,912,132	06-15-1999	Brann	
	9	5,955,281	09-21-1999	Brann	
	10	6,107,324	08-22-2000	Behan, et al.	
	11	6,140,509	10-31-2000	Behan, et al.	
	12	6,150,393	11-21-2000	Behan, et al.	
	13	6,358,698	03-19-2002	Weiner, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
	14	CA 984843	03-02-1976	John Wyeth & Brother Limited		
	15	EP 0 005 318 A1	11-14-1979	Janssen Pharm.		
	16	EP 0 379 441 A1	07-25-1990	Rhone-Poulenc Sante		
	17	EP 0 548 015 A1	06-23-1993	Ciba-Geigy AG		
	18	WO 97/08166 A1	03-06-1997	Schering Corporation		
	19	WO 97/11940 A1	04-03-1997	Eli Lilly and Company		
	20	WO 98/11128 A1	03-19-1998	Dr. Karl Thomae GMBH		
	21	WO 98/17846 A1	04-30-1998	Dr. Karl Thomae GMBH		
	22	WO 99/52927 A1	10-21-1999	Arena Pharmaceuticals, Inc.		
	23	WO 00/56335 A1	09-28-2000	The Regents of the University of California		
	24	WO 00/69810 A1	11-23-2000	Novo Nordisk A/S		
	25	WO 03/070246 A1	08-28-2003	Pfizer Products Inc.		

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 2 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	26	ADAM, et al. 1989. Effects of repeated ritanserin on middle-aged poor sleepers. <i>Psychopharmacology</i> , 99:219-221.	
	27	ADELL, et al. 2006. Strategies for producing faster acting antidepressants. <i>Drug Discovery Today</i> , 10(8):578-585.	
	28	AKIN, et al. 2004. Decreased serotonin 5-HT <sub>2A</sub> receptor-stimulated phosphoinositide signaling in fibroblasts from melancholic depressed patients. <i>Neuropsychopharmacology</i> , 29:2081-2087.	
	29	ALVISI, N. 1892. Sulla formazione di derivati pirazolici dalla dicloridrina e dalla tribromidrina della glicerina ordinaria, <i>Gazz. Chem. Ital.</i> 22:158-168.	
	30	ANTILLA, et al. 2001. Copper-catalyzed coupling of arylboronic acids and amines. <i>Organic Letters</i> , 3(13):2077-2079.	
	31	ANTILLA, et al. 2002. The copper-catalyzed N-arylation of indoles. <i>J. Am. Chem. Soc.</i> , 124:11684-11688.	
	32	ARTICO, et al. 1992. Aromatic hydrazides as specific inhibitors of bovine serum amine oxidase. <i>Eur. J. Med. Chem.</i> , 27:219-228.	
	33	BARCHAS, J. 1973. Serotonin and Behavior. New York: Academic Press.	
	34	BASSUS, et al. 1974. Psychotropes potentiels. X. Synthèse de butyrophénones à cycle pipéridine-spiro-tétrahydroxazinone douées d'activité neuroleptique. <i>Eur. J. Med. Chem. - Chimie Therapéutique</i> , 9(4):416-423.	
	35	BENNETT, et al. 1993. Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms. <i>Neurology</i> , 43:1551-1556.	
	36	BHATIA, et al. 1996. 5-Lipoxygenase inhibitors: Synthesis and structure-activity relationships of a series of 1-Aryl-2,4,4-tetrahydro-1,2,4-triazin-3-ones. <i>J. Med. Chem.</i> , 39:3936-3950.	
	37	BIAGI, et al. 1988. 1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis in vitro. <i>Pharmacol. Ed. Sci.</i> , 43:597-612.	
	38	BIBBIANI, et al. 2001. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. <i>Neurology</i> , 57:1829-1834.	
	39	BIRKMAYER, et al. 1974. Nucleus ruber and L-Dopa psychosis: Biochemical post-mortem findings. <i>Journal of Neural Transmission</i> , 35:93-116.	
	40	BLAKLEY, et al. 2001. Bidirectional changes in ethanol consumption in rats with site-specific antisense down-regulation of 5-hydroxytryptamine <sub>2A</sub> receptors in brain. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 299(1):277-289.	
	41	BLIER, et al. 2001. Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain. <i>Journal of Psychiatry &amp; Neuroscience</i> , 26(1):37-43.	
	42	BLIER, et al. 2005. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. <i>J. Clin. Psychiatry</i> , 66(suppl 8):30-40.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 3 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnson
		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	43	BROWN, et al. 1924. Catalytic alkylation of aniline. <i>J. Am. Chem. Soc.</i> , 46(8):1836-1839.	
	44	BÜCHI, et al. 1969. Synthesis of (±)-nuciferol. <i>J. Org. Chem.</i> , 34(4):1122-1123.	
	45	BUTCHER, et al. 1970. L-Dopa induced changes in central monoamine neurons after peripheral decarboxylase inhibition. <i>Letters to the Editor, J. Pharm. Pharmac.</i> , 22:313-316.	
	46	BUU-HOT, et al. 1951. Further studies in the alkylation of phenols and thiophenols. <i>J. Org. Chem.</i> , 16:988-994.	
	47	CACCHI, et al. 2003. Palladium-catalyzed reaction of aryl iodides with acetic anhydride. A carbon monoxide-free synthesis of acetophenones. <i>Organic Letters</i> , 5(3):289-291.	
	48	CARMAN, et al. 1998. A further synthesis of an analogue of the antifungal/antiherbivore lipid from avocado. <i>Aust. J. Chem.</i> , 51:955-959.	
	49	CATARZI, et al. 2001. Synthesis, ionotropic glutamate receptor binding affinity, and structure-activity relationships of a new set of 4,5-dihydro-8-heterocyl-4-oxo-1,2,4-triazolo[1,5-a]quinoxaline-2-carboxylates analogues of TQX-173. <i>J. Med. Chem.</i> , 44:3157-3165.	
	50	Chemical Abstracts, 128:111548. BRANN, M. R. 1998. Identification of ligands by selective amplification of cells transfected with receptors and marker enzymes.	
	51	CLARK, et al. 1983. Antihypertensive 9-substituted 1-Oxa-4,9-diazaspiro[5.5]undecan-3-ones. <i>J. Med. Chem.</i> , 26:855-861.	
	52	DeCLERCK, et al. 1987. Increase in slow-wave sleep in humans with the serotonin-S <sub>2</sub> antagonist ritanserin. <i>Current Therapeutic Research</i> , 41(4):427-432.	
	53	DUNN, et al. 1986. Analgetic and antiinflammatory 7-arylobenzofuran-5-ylacetic acids and 7-arylbenzothiopheno-5-ylacetic acids. <i>J. Med. Chem.</i> , 29:2326-2329.	
	54	DURIF, et al. 1997. Low-dose clozapine improves dyskineticas in Parkinson's disease. <i>Neurology</i> , 48:658-662.	
	55	EMERSON, et al. 1938. The reductive alkylation of aniline. <i>J. Am. Chem. Soc.</i> , 60:2023-2025.	
	56	ERMAKOV, et al. 1981. Use of Mass spectrometry in structural and stereochemical studies. <i>Chemistry of Heterocyclic Compounds</i> , 1:72-77.	
	57	EVERETT, et al. 1970. L-Dopa: Effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. <i>Science</i> , 168:849-850.	
	58	FINAR, et al. 1954. The preparation and properties of some derivatives of 1-phenylpyrazole. <i>J. Chem. Soc.</i> , pp. 2293-2298.	
	59	FIŠERA, et al. 1994. Synthesis of spiro-substituted 1,3-oxazines by a new sequence leading to spiroheterocycles. <i>Monatsh. für Chemie</i> , 125:909-919.	
	60	FRIEDMAN, et al. 1999. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. <i>N. Engl. J. Med.</i> , 340(10):757-763.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 4 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	61	FRIEDMAN, et al. 2000. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. <i>Movement Disorders</i> , 15(2):201-211.	
	62	GAINETDINOV, et al. 2001. Genetic animal models: Focus on schizophrenia. <i>Trends in Neurosciences</i> , 24(9):527-533.	
	63	GAMMA, et al. 2000. 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [ $H_2^{18}O$ ]-PET in healthy humans. <i>Neuropsychopharmacology</i> , 23(4):388-395.	
	64	GAWLEY, R. E., & Aubé, J. 1996. <i>Principles of Asymmetric Synthesis</i> . New York: Pergamon.	
	65	GILLMAN, P. K. 2005. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. <i>British Journal of Anaesthesia</i> , 95(4):434-441.	
	66	GOOSEN, et al. 2001. Palladium-catalyzed synthesis of aryl ketones from boronic acids and carboxylic acids or anhydrides. <i>Angew. Chem. Int. Ed.</i> , 40:3458-3460.	
	67	GSTACH, et al. 1990. Rearrangement of 3,3-disubstituted 1-aryl-4,5-dihydro-5-oxo-3H-1,2,4-triazolium tetrafluoroborates: Part 1. A versatile synthesis of 1,5-disubstituted 2-aryl-1,2-dihydro-3H-1,2,4-triazol-3-one tetrafluoroborates. <i>Synthesis</i> , pp. 803-808.	
	68	GUTHRIE, et al. 1983. The tetrahedral intermediate from the hydration of <i>N</i> -methylformenilide. <i>Can. J. Chem.</i> , 71:2109-2122.	
	69	HARTWIG, J. F. 1988. Transition metal catalyzed synthesis of arylamines and aryl ethers from aryl halides and triflates: Scope and mechanism. <i>Angew. Chem. Int. Ed.</i> , 37:2047-2087.	
	70	HICKINBOTTOM, W. J. 1930. The preparation of secondary alkylaryl-amines and their purification. <i>J. Chem. Soc.</i> , pp. 992-994.	
	71	HIRST, et al. 1895. A method for preparing the formyl derivatives of the aromatic amines. <i>J. Chem. Soc.</i> , 67:829-831.	
	72	IDZIKOWSKI, et al. 1991. A dose response study examining the effects of ritanserin on human slow wave sleep. <i>Br. J. Clin. Pharmac.</i> , 31:193-196.	
	73	JAEGER, et al. 1941. Two ketones of the stilboestrol group. <i>J. Chem. Soc.</i> , 744-747.	
	74	KANAYAMA, et al. 2005. New treatment of lumbar disc herniation involving 5-hydroxytryptamine <sub>2A</sub> receptor inhibitor: A randomized controlled trial. <i>J. Neurosurg: Spine</i> , 2:441-446.	
	75	KLAPARS, et al. 2001. A general and efficient copper catalyst for the amidation of aryl halides and the <i>N</i> -arylation of nitrogen heterocycles. <i>J. Am. Chem. Soc.</i> , 123:7727-7729.	
	76	KLAPARS, et al. 2002. A general and efficient copper catalyst for the amidation of aryl halides. <i>J. Am. Chem. Soc.</i> , 124:7421-7428.	
	77	KWONG, et al. 2002(a). Copper-catalyzed coupling of alkylamines and aryl iodides: An efficient system even in an air atmosphere. <i>Organic Letters</i> , 4(4):581-584.	
	78	KWONG, et al. 2002(b). A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols. <i>Organic Letters</i> , 4(20):3517-3520.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 5 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	79	KWONG, et al. 2003. Mild and efficient copper-catalyzed amination of aryl bromides and primary alkylamines. <i>Organic Letters</i> , 5(6):793-796.	
	80	LANDINI, et al. 1974. A convenient synthesis of primary and secondary dialkyl and aryl alkyl sulfides in the presence of phase-transfer catalysts. <i>Synthesis</i> , pp. 565-566.	
	81	LANDOLT, et al. 1999. Serotonin-2 receptors and human sleep: Effect of a selective antagonist on EEG power spectra. <i>Neuropsychopharmacology</i> , 21(3):455-466.	
	82	LEYSEN, et al. 1978. Serotonergic component of neuroleptic receptors. <i>Nature</i> , 272:168-171.	
	83	LI, G. Y. 2002. Highly active, air-stable palladium catalysts for the C-C and C-S bond-forming reactions of vinyl and aryl chlorides: Use of commercially available $[(t\text{-Bu})_2\text{P}(\text{O})\text{H}]_2\text{PdCl}_2$ , $[(t\text{-Bu})_2\text{P}(\text{O})\text{H}]_2\text{PdCl}_2$ , and $[(t\text{-Bu})_2\text{PO}.\text{H}_2\text{O}][\text{PdCl}_2]$ as catalysts. <i>J. Org. Chem.</i> , 67:3643-3650.	
	84	LIECHTI, et al. 2001. Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with Citalopram, Haloperidol, or Ketanserin. <i>Neuropsychopharmacology</i> , 24(3):240-252.	
	85	MAREK, et al. 2003. Synergistic action of 5-HT <sub>2A</sub> antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders. <i>Neuropsychopharmacology</i> , 28:402-412.	
	86	MAREK, et al. 2005. The selective 5-HT <sub>2A</sub> receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine. <i>Neuropsychopharmacology</i> , 30:2205-2215.	
	87	MAVUNKEL, et al. 1996. Synthesis and characterization of pseudo-peptide bradykinin B2 receptor antagonists containing the 1,3,8-triazaspiro[4.5]decan-4-one ring system. <i>J. Med. Chem.</i> , 39:3169-3173.	
	88	MAYER, et al. 2003. Ritanterine improves sleep quality in narcolepsy. <i>Psychopharmacology</i> , 164:150-155.	
	89	MELTZER, et al. 1995. Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson's disease. <i>Neuropsychopharmacology</i> , 12(1):39-45.	
	90	MENG, et al. 1991. Synthetic approaches toward glidobamine, the core structure of the glidobactin antibiotics. <i>Tetrahedron</i> , 47(32):62510-6284.	
	91	MILČOVIĆ, et al. 1991. A simple method for preparation of secondary aromatic amines. <i>Synthesis</i> , 11:1043-1045.	
	92	MIYATA, et al. 2000. Saroprelate, a selective 5-HT <sub>2A</sub> serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. <i>Journal of Cardiovascular Pharmacology</i> , 35(2):294-301.	
	93	MOULIGNIER, A. 1994. Récepteurs centraux de la sérotonine principaux aspects fondamentaux et fonctionnels application thérapeutiques. <i>Rev. Neurol.</i> , 150:3-15.	
	94	MOULIGNIER, A. 1994. Récepteurs centraux de la sérotonine principaux aspects fondamentaux et fonctionnels application thérapeutiques. <i>Rev. Neurol.</i> , 150:3-15.	✓ (Abstract)
	95	MOUNÉ, et al. 1997. Total synthesis of dolatrienolic acid: A subunit of dolastatin 14. <i>J. Org. Chem.</i> , 62:3332-3339.	

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 6 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	96	MULLEN et al. 2000. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the $\alpha 7$ nicotinic acetylcholine receptor. <i>J. Med. Chem.</i> , 43:4045-4050.	
	97	MURI, et al. 1998. Synthesis of new benzylidene ethers of oximes derived from 1-phenyl-pyrazole compounds. <i>Synthetic Communications</i> , 28(7):1299-1321.	
	98	NG, et al. 1970. L-dopa-induced release of cerebral monoamines. <i>Science</i> , 170:76-77.	
	99	NIGAM, et al. 1957a. Studies with acetylenes. Part II. Some reactions of Grignard reagents with propargylic halides. Model linoleic and linolenic acid systems. <i>J. Chem. Soc.</i> , pp. 3888-3873.	
	100	NIGAM, et al. 1957b. The conversion of fatty acids into aldehydes. <i>J. Chem. Soc.</i> , pp.3320-3321.	
	101	NORDSTROM, et al. 1993. High 5-HT <sub>2</sub> receptor occupancy in clozapine treated patients demonstrated by PET. <i>Psychopharmacology</i> , 110:365-367.	
	102	OGAWA, et al. 2006. Effects of R-102444 and its active metabolite R-96544, selective 5-HT <sub>2A</sub> receptor antagonists, on experimental acute and chronic pancreatitis: Additional evidence for possible involvement of 5-HT <sub>2A</sub> receptors in the development of experimental pancreatitis. <i>European Journal of Pharmacology</i> , 521:156-163.	
	103	OLÄH, et al. 1956. Notiz über die N-Formylierung von Aminen mit Formylfluorid. <i>Chem. Ber.</i> , 89:2211-2212.	
	104	OLD, et al. 2002. Efficient palladium-catalyzed N-arylation of indoles. <i>Organic Letters</i> , 2(10):1403-1406.	
	105	PAIVA, et al. 1988. Effects of ritanserin on sleep disturbances of dysthymic patients. <i>Psychopharmacology</i> , 96:395-399.	
	106	PATEL, et al. 2004. The highly selective 5-hydroxytryptamine (5-HT) <sub>2A</sub> receptor antagonist, EMD 281014, significantly increases swimming and decreases immobility in mice congenital learned helpless rats in the forced swim test. <i>Synapse</i> , 52:73-75.	
	107	PIERCE, et al. 1995. 5-hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 275(1):502-508.	
	108	POLLAIK, et al. 1999. Clozapine in drug-induced psychosis in Parkinson's disease. <i>The Lancet</i> , 353:2041-2042.	
	109	READ, W. T. 1922. Researches on hydantoin. Synthesis of the soporific, 4,4-phenylethyl-hydantoin(nirvanol). <i>J. Am. Chem. Soc.</i> , 44:1746-1755.	
	110	RICCI, A. 2000. <i>Modern Animation Methods</i> . New York: Wiley-VCH.	
	111	RICE, et al. 1955. Raney nickel catalyzed N-alkylation of aniline and benzidine with alcohols. <i>J. Am. Chem. Soc.</i> , 77:4052-4054.	
	112	RUBIRALTA, M., Giralt, E., & Diez, A. 1991. <i>Studies in Organic Chemistry 43. Piperidine: Structure, Preparation, Reactivity and Synthetic Applications of Piperidine and its Derivatives</i> . New York: Elsevier.	

Examiner Signature

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 7 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
113	SADZOT, et al. 1989. Hallucinogenic drug interactions at human brain 5-HT <sub>2</sub> receptors: Implications for treating LSD-induced hallucinogenesis. <i>Psychopharmacology</i> , 98:495-499.		
114	SCHINS, et al. 2003. Increased coronary events in depressed cardiovascular patients: 5-HT <sub>2A</sub> receptor as missing link? <i>Psychosomatic Medicine</i> , 65:729-737.		
115	SCRETTAS, et al. 1978. Hydrolithiation of $\alpha$ -olefins by a regiospecific two-step process. Transformation of alkyl phenyl sulfides to alkylthium reagents. <i>J. Org. Chem.</i> , 43(6):1064-1071.		
116	SHARPLEY, et al. 1994. Slow wave sleep in humans: Role of 5-HT <sub>2A</sub> and 5-HT <sub>2C</sub> receptors. <i>Neuropharmacology</i> , 33(3/4):467-471.		
117	STEFANCICH, et al. 1994. Agenti antiinfiammatori non-steroidi: Nota III – sintesi ed attività analgesica-antinfiammatoria di 4-(pirolo-1-il)-fenilacetamidi e di 4-(pirolo-1-il)fenetilamine. <i>Farmaco Ed. Sci.</i> , 39(9):752-764.		
118	STRYJER, et al. 2003. Treatment of neuroleptic-induced akathisia with the 5-HT <sub>2A</sub> antagonist trazodone. <i>Clinical Neuropharmacology</i> , 26(3):137-141.		
119	TSUKAMOTO, et al. 1995. Synthesis and structure-activity studies of a series of 1-oxa-2,8-diazaspiro[4.5]decan-3-ones and related compounds as M <sub>1</sub> muscarinic agonists. <i>Chem. Pharm. Bull.</i> , 43(9):1523-1529.		
120	VAN LAAR, et al. 2001. Subchronic effects of the GABA-agonist lorazepam and the 5-HT <sub>2A/C</sub> antagonist ritanserin on driving performance, slow wave sleep and daytime sleepiness in healthy volunteers. <i>Psychopharmacology</i> , 154:189-197.		
121	VIOLA, et al. 2002. Rilseren, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers. <i>Clinical Neurophysiology</i> , 113:429-434.		
122	VOGEL, A. I. 1948. Physical properties and chemical constitution. Part XIX. Five-membered and six-membered carbon rings. <i>J. Chem. Soc.</i> , pp. 1809-1813.		
123	VOGL, et al. 2002. Palladium-catalyzed monoarylation of nitroalkanes. <i>J. Org. Chem.</i> , 67(1):106-111.		
124	WEINER, et al. 2001. 5-Hydroxytryptamine <sub>2A</sub> receptor inverse agonists as anti psychotics. <i>The Journal of Pharmacology and Experimental Therapeutics</i> , 299(1):268-276.		
125	WHITMORE, et al. 1942. Abnormal Grignard reactions. XII. Sterically hindered aliphatic carbonyl compounds. II. Ketones containing the dineopentylcarbinyl group. <i>J. Am. Chem. Soc.</i> , 64:1247-1251.		
126	WHITMORE, et al. 1947. Higher hydrocarbons. IV. Six phenyleicosanes and six cyclohexyleicosanes. <i>J. Am. Chem. Soc.</i> , 69:235-237.		
127	WOLF, V. V. 1952. Über alkin-amine I. Aryl-propargyl-amine. <i>Liebigs Ann. Chem.</i> , 576:35-45.		
128	WOLFE, et al. 1996. An improved catalyst system for aromatic carbon-nitrogen bond formation: The possible involvement of bis(phosphine) palladium complexes as key intermediates. <i>J. Am. Chem. Soc.</i> , 118:7215-7216.		
129	YAMADA, et al. 1998. Alternative synthesis of TTF donors with a dioxolane ring, and synthesis of their dithiolane and oxathiolane analogues. <i>Tetrahedron Letters</i> , 39:7709-7712.		

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application No.	10/802,970
(Multiple sheets used when necessary)		Filing Date	March 16, 2004
SHEET 8 OF 8		First Named Inventor	Carl-Magnus Andersson
		Art Unit	1624
		Examiner	Jason H Johnsen
		Attorney Docket No.	ACADIA.014C2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
	130	YANG, et al. 1999. Palladium-catalyzed amination of aryl halides and sulfonates. <i>Journal of Organometallic Chemistry</i> , 576:125-146.	
	131	YASUHARA, et al. 2000. An activated phosphate for an efficient amide and peptide coupling reagent. <i>J. Chem. Soc., Perkin Trans. 1</i> , 17:2901-2902.	
	132	YIN, et al. 2002. Pd-catalyzed intermolecular amidation of aryl halides: The discovery that xantphos can be trans-chelating in a palladium complex. <i>J. Am. Chem. Soc.</i> , 124:8043-8048.	

3480922  
030207

Examiner Signature	Date Considered
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.